Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 5Breast 5Gastrointestinal 4Genitourinary 2Dermatologic 2

Conditions

Melanoma 2Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
tesetaxel × Dermatologic × Clear all
NCT01064713 2018-07-17

Phase II Study of Tesetaxel in Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
17 enrolled 5 charts
Dermatologic

Melanoma, Neoplasms

NCT01092585 2011-11-08

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Genta Incorporated

Phase 2 Unknown
27 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡